Cardinal Health raises FY25 EPS guidance to $7.85-$8

Cardinal Health raises FY25 EPS guidance to $7.85-$8 amid specialty growth and acquisitions
Q2 2025 Management View CEO Jason Hollar emphasized strong Q2 performance driven by robust demand in Pharmaceutical and Specialty Solutions, particularly in brand, specialty, generics, and consumer health segments.
Cardinal Health lifts 2025 profit forecast on specialty drugs demand
Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.
Cardinal Health price target raised to $156 from $138 at Leerink
Leerink raised the firm’s price target on Cardinal Health (CAH) to $156 from $138 and keeps an Outperform rating on the shares. Q2 results
Cardinal Health reports Q2 results, raises fiscal year 2025 outlook
Cardinal Health's pharmaceutical and specialty solutions segment profit increased 7% to $531 million in the second quarter.
Cardinal Health may raise prices to offset potential tariffs
By Christy Santhosh and Kamal Choudhury (Reuters) -Drug distributor Cardinal Health said on Thursday it may need to increase prices of some of its products if the proposed tariffs on Mexico go into effect,
Cardinal Health raises FY25 EPS view to $7.85-$8.00 from $7.75-$7.90
Consensus $7.86. The company said, “The company raised its fiscal 2025 guidance range for non-GAAP diluted earnings per share attributable to
Citi raises Cardinal Health stock target to $130 on Pharma strength
Citi analyst Daniel Grosslight increased the price target for Cardinal Health (NYSE:CAH) shares to $130 from the previous $129, while keeping a Neutral rating on the stock. The adjustment follows Cardinal Health's recent financial performance,
Cardinal Health Inc (CAH) Q2 2025 Earnings Call Highlights: Strong Pharma Growth Amid Revenue ...
Cardinal Health Inc (CAH) raises EPS guidance despite a 4% revenue decline, driven by robust pharmaceutical segment ...
Modern Healthcare14h
Cardinal Health CEO Jason Hollar issues warning on tariffs
Cardinal Health warned Thursday that if President Donald Trump follows through with threatened tariffs next month, higher ...
Positive Financial Prospects Drive Buy Rating for Cardinal Health Amid Raised Guidance and Strong Segment Performance
Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on Cardinal Health (CAH – Research Report). The associated price target was ...
Cardinal Health, Inc. (CAH) Q2 2025 Earnings Call Transcript
Hello, and welcome to the Second Quarter Fiscal Year 2025 Cardinal Health Inc. Earnings Conference Call. My name is George, and I'll be coordinator for today's event. Please note, this conference is ...
MDM14h
Cardinal Health 2Q Sales Rise 16% Outside of Optimum Impact
Cardinal Health reported an increase in revenue for two of its segments, while the departure of Optimum impacted its Pharmaceuticals segment.
Hoodline14h
Dublin City Schools Abandons Cardinal Health Building Purchase, Opts for Scioto High School Expansion
Dublin City Schools has officially backed out of a deal to acquire the vacant Cardinal Health office building, pivoting ...
Here's Why Cardinal Health (CAH) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks.com on MSN15h
CAH Q2 Earnings and Sales Beat Estimates, 2025 EPS View Raised
Cardinal Health, Inc. CAH reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.93, which beat the ...